Core Insights - Shandong Furuida Biological Co., Ltd. is the only beauty industry company recognized as a national quality benchmark, highlighting its authority in intelligent quality management throughout the product lifecycle [1][24][27] - The company's success aligns with China's goal of transitioning from a "manufacturing powerhouse" to a "quality powerhouse" in the cosmetics industry [3][26] Group 1: Quality Management Achievements - Furuida Biological has established a comprehensive traceable quality management system covering the entire product lifecycle, with over 1,000 quality control documents totaling more than 2.1 million words [30] - The company has received multiple authoritative certifications, including ISO22716/GMPC and CNAS, and has been recognized as a model enterprise for cosmetic production quality in Shandong Province [30][28] - Furuida's management philosophy incorporates a PDCA (Plan-Do-Check-Act) cycle, fostering a culture of quality participation among all employees [30][28] Group 2: Digital Transformation and Innovation - The company has transitioned its quality control from manual to a combination of technical and digital defenses, creating a comprehensive quality traceability loop across research and development, production, supply chain, and marketing [8][10] - Furuida has developed four major digital collaborative platforms, including transparent, green, and intelligent factories, to ensure a closed-loop management system focused on prevention and process control [33][10] - The establishment of a PLM (Product Lifecycle Management) system has improved research efficiency and resource reuse by over 30%, while on-time order fulfillment rates have increased by 19% [34][35] Group 3: Supply Chain and Marketing Strategies - The ERP-based supply chain platform allows for digital grading and management of suppliers, ensuring traceability from supplier admission to product delivery [38] - A unique traceability system assigns a unique code to each product, enabling consumers to verify authenticity and creating a "quality responsibility community" across the supply chain [38] - Furuida's marketing strategy integrates user feedback through a CRM system, enhancing service experience and driving product improvement based on real-time data analysis [39][40] Group 4: Industry Impact and Future Directions - Furuida's practices set a high standard for the beauty industry, providing a replicable and scalable path for quality enhancement in Chinese cosmetics [43][20] - The company aims to deepen the application of quality benchmark experiences and empower the industry, focusing on brand culture, technological innovation, and digital ecosystem reconstruction [44][45]

每经头条（nbdtoutiao）——直击茅台经销商大会：2000多人周末齐聚！重大变革公布：涉及茅台酒价 格、分销等，董事长陈华：经销商不能再"躺着赚钱" 截至发稿，福瑞达市值为75亿元。 每经AI快讯，福瑞达（SH 600223，收盘价：7.35元）12月29日晚间发布公告称，公司第十二届2025年 第五次董事会临时会议于2025年12月29日以通讯方式召开。会议审议了《关于公司2026年度日常关联交 易预计发生金额的议案》等文件。 2025年1至6月份，福瑞达的营业收入构成为：化妆品占比61.13%，物业出租占比16.37%，药品占比 11.57%，添加剂占比9.98%，其他业务占比0.95%。 （记者 王晓波） ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-034 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易概述 2026 年，鲁商福瑞达医药股份有限公司（以下简称"公司"）根据日常经营和 业务发展的需要，公司（包括下属子公司）与公司第一大股东山东省商业集团有 限公司及其关联企业发生提供或接受劳务、采购或销售商品、房屋租赁等日常关 联交易，双方将遵循公平、有偿、互利的市场原则进行交易，在发生关联交易时 签署有关的协议或合同。 （二）日常关联交易履行的审议程序 1、董事会表决情况和关联董事回避情况：公司第十二届董事会2025年第五次 临时会议审议通过了《关于公司2026年度日常关联交易预计发生金额的议案》， 在参与本次表决的5名董事中关联董事2名，非关联董事3名（含独立董事2名），会 议以3票同意，0票反对，0票弃权，2名关联董事回避的表决结果通过该议案。 对于上述额度内的关联交易，公司提请股东会授权公司（包括下属子公司） 在发生关联交易时签署有关的协议或合同，并授权经营层在关联交易预计总额范 围内根据具体情况适当调整具体类别及额度。 2、公司第十二届独立董事专门会议审议通过了《关于公司 ...

鲁商福瑞达医药股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 14 日 议案 关于公司 2026 年度日常关联交易预计发生金额的议案 （二）2025年度日常关联交易的预计和执行情况 注：上述关联交易实际发生额比预计金额减少，主要是根据公司生产 经营的实际进度与招标情况，采购额较年初计划减少所致。 （三）2026 年度日常关联交易预计金额和类别 各位股东及股东代表： 一、日常关联交易基本情况 （一）日常关联交易概述 2026 年，公司根据日常经营和业务发展的需要，公司（包括下属 子公司）与公司第一大股东山东省商业集团有限公司及其关联企业发 生提供或接受劳务、采购或销售商品、房屋租赁等日常关联交易，双 方将遵循公平、有偿、互利的市场原则进行交易，在发生关联交易时 签署有关的协议或合同。 2 2．与上市公司的关联关系 山东省商业集团有限公司持有公司 524,739,200 股，占公司总股 本的 51.62%，是本公司第一大股东。 3．履约能力分析 上述关联人财务状况和经营情况良好，具备履约能力，上述关联 交易系本公司正常经营所需。 三、定价政策和定价依据 上述关联交易为公司日常经营行为，以 ...

证券代码：600223 证券简称：福瑞达 公告编号：2025-035 鲁商福瑞达医药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东会类型和届次 2026年第一次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2026 年 1 月 14 日 15 点 00 分 召开地点：山东省济南市高新区新泺大街 888 号公司会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 14 日 至2026 年 1 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-033 一、通过《关于公司2026年度日常关联交易预计发生金额的议案》，该议案 已经公司独立董事专门会议审议通过，尚需提交公司2026年第一次临时股东会审 议，具体事项详见《鲁商福瑞达医药股份有限公司关于2026年度日常关联交易预 计发生金额的公告》（临2025-034）。 由于该议案涉及关联交易，在参与本次表决的5名董事中关联董事2名，非关 联董事3名（含独立董事2名），会议以3票同意，0票反对，0票弃权，2名关联董 事回避的表决结果审议通过。 二、全票通过《关于召开2026年第一次临时股东会的议案》，公司定于2026 年1月14日15：00时在山东省济南市高新区新泺大街888号公司会议室召开公司 2026年第一次临时股东会，具体内容详见《鲁商福瑞达医药股份有限公司关于召 开2026年第一次临时股东会的通知》（2025-035）。 特此公告。 鲁商福瑞达医药股份有限公司董事会 2025年12月30日 鲁商福瑞达医药股份有限公司 第十二届董事会 2025 年第五次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述 ...

经参会独立董事审议，一致通过《关于公司 2026 年度日常关联交易预计发生金 额的议案》，独立董事认为：根据公司经营的需要，公司（包括下属子公司）将与公 司控股股东山东省商业集团有限公司及其关联企业在提供或接受劳务、采购或销售 商品、房屋租赁等方面发生日常经营性关联交易，并遵循客观、公正的原则和市场 化定价方式进行，未损害公司其他股东的利益。上述关联交易未影响公司的独立性， 公司主要业务亦未因上述关联交易而对关联人形成依赖。同意将该议案提交公司第 十二届董事会 2025 年第五次临时会议审议。 鲁商福瑞达医药股份有限公司 第十二届董事会独立董事专门会议决议 独立董事：宿玉海、朱德胜 2025 年 12 月 30 日 鲁商福瑞达医药股份有限公司（以下简称"公司"）第十二届董事会独立董事专 门会议于 2025 年 12 月 21 日发出通知，并于 2025 年 12 月 26 日在公司会议室召开。 经过半数独立董事共同推举，本次会议由独立董事宿玉海召集和主持，本次会议应 参会独立董事 2 名，实际参加表决的独立董事 2 名，本次会议的召集、召开符合《中 华人民共和国公司法》《上市公司独立董事管理办法》《公司章程》 ...

Group 1 - The cosmetics sector experienced a decline of 1.26% on December 29, with Shanghai Jahwa leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] - Key individual stock performances in the cosmetics sector included Qingdao Kingway up 1.38% and Shanghai Jahwa down 3.06% [2] Group 2 - The net outflow of main funds in the cosmetics sector was 94.94 million yuan, while retail funds saw a net inflow of 41.59 million yuan [2] - The main fund flow for Shanghai Jahwa showed a net outflow of 1.0677 million yuan, with retail funds showing a net inflow of 2.0905 million yuan [3] - Qingdao Kingway had a significant net outflow of 24.09 million yuan from main funds, while retail funds experienced a net outflow of 23.17 million yuan [3]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]

Market Overview - The cosmetics sector experienced a slight decline of 0.13% on December 26, with Qingsong Co. leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Individual Stock Performance - Marubi Biotechnology (603983) closed at 33.09, up 0.91% with a trading volume of 23,700 shares and a turnover of 78.26 million yuan [1] - Shanghai Jahwa (600315) closed at 23.17, up 0.83% with a trading volume of 32,000 shares and a turnover of 74.08 million yuan [1] - Furuida (600223) closed at 7.39, up 0.41% with a trading volume of 55,100 shares and a turnover of 40.71 million yuan [1] - Proya Cosmetics (603605) closed at 67.92, up 0.06% with a trading volume of 27,900 shares and a turnover of 20.06 million yuan [1] - Betaini (300957) closed at 40.48, down 0.59% with a trading volume of 37,100 shares and a turnover of 151 million yuan [1] - Other notable declines include Qingsong Co. (300132) down 1.57% and Jinsong New Materials (300849) down 1.55% [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 80.47 million yuan from institutional investors, while retail investors contributed a net inflow of 70.02 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Furuida (600223) had a net inflow of 7.77 million yuan from institutional investors, but a net outflow of 4.35 million yuan from retail investors [3] - Huaye Fragrance (300886) saw a net inflow of 3.30 million yuan from institutional investors, while retail investors had a net outflow of 1.01 million yuan [3] - Marubi Biotechnology (603983) experienced a net inflow of 1.22 million yuan from institutional investors, with retail investors also seeing a net outflow [3] - Qingsong Co. (300132) had a significant net outflow of 1.57 million yuan from institutional investors [3]